Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.60
-0.30 (-3.80%)
At close: Nov 18, 2025, 4:00 PM EST
7.61
+0.01 (0.07%)
After-hours: Nov 18, 2025, 4:07 PM EST
Lifecore Biomedical Revenue
In the fiscal year ending May 25, 2025, Lifecore Biomedical had annual revenue of $128.87M with 0.47% growth. Lifecore Biomedical had revenue of $31.11M in the quarter ending September 30, 2025, with 25.92% growth.
Revenue (ttm)
$128.87M
Revenue Growth
+0.47%
P/S Ratio
2.13
Revenue / Employee
$317,406
Employees
406
Market Cap
284.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 25, 2025 | 128.87M | 606.00K | 0.47% |
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 26, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 27, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 28, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 29, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LFCR News
- 7 days ago - Lifecore Biomedical to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update - GlobeNewsWire
- 19 days ago - Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 - GlobeNewsWire
- 20 days ago - Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company - GlobeNewsWire
- 21 days ago - Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market - GlobeNewsWire
- 5 weeks ago - Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events - GlobeNewsWire
- 2 months ago - Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire